PA-111

PA-111 is a **small molecule drug** in clinical development for the treatment of **dyslipidemias**, a group of disorders characterized by abnormal lipid levels in the blood. It is being developed by Addpharma and is currently in **Phase 1 clinical trials** as of April 2025. The primary therapeutic area for PA-111 is endocrinology and metabolic diseases. Its precise **mechanism of action has not been disclosed** in publicly available sources, nor has its specific molecular target been detailed. The available Phase 1 trial is an open-label, randomized, single-dose, crossover study designed to evaluate the safety and pharmacokinetic characteristics of PA-111 compared to a related compound, PA-111A, in healthy adult volunteers under fed conditions[1][3].